Understanding Psoriasis in the UK Context

Psoriasis is a chronic autoimmune skin condition characterised by rapid skin cell growth, leading to thick, scaly patches that can be itchy, painful, and embarrassing. In the United Kingdom, it affects approximately 2% of the population, equating to around 1.3 million people, with onset typically in adults aged 20-30 or 50-60. The condition arises from an overactive immune response where T-cells trigger inflammation, causing keratinocytes to proliferate excessively. Beyond the skin, psoriasis increases risks for comorbidities like psoriatic arthritis (affecting up to 30% of patients), cardiovascular disease, type 2 diabetes, and metabolic syndrome, underscoring its systemic nature.

Current management relies on topical treatments, phototherapy, and systemic biologics for moderate-to-severe cases, yet response varies widely. This heterogeneity highlights the need for precision approaches, where genetic and molecular insights can guide therapy selection, reducing trial-and-error and improving outcomes for UK patients.

The PSORT Consortium's Groundbreaking Research

Led by researchers at Newcastle University and Queen Mary University of London, the PSORT (Personalised psoriasis therapy: prediction of treatment response) consortium has delivered a landmark publication in Communications Medicine on 21 January 2026. Titled 'Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity', the study analysed RNA sequencing data from 718 skin and blood samples across 146 patients with moderate-to-severe plaque psoriasis. Patients were initiating either adalimumab (TNF-inhibitor) or ustekinumab (IL-12/23-inhibitor), with samples collected at baseline and weeks 1, 4, and 12.

Key investigators include Ashley Rider and Nick J. Reynolds from Newcastle University's Institute of Translational and Clinical Medicine, alongside collaborators from the University of Manchester, King's College London, and others. Funded by the Medical Research Council, British Association of Dermatologists, Psoriasis Association, NIHR Newcastle Biomedical Research Centre, and Rosetrees Trust, this work exemplifies collaborative higher education research driving clinical innovation.

🔬 Innovative Methods: From RNA Sequencing to AI-Driven Analysis

The study employed comprehensive transcriptomic profiling via RNA sequencing on lesional, non-lesional skin biopsies, and peripheral blood. Advanced bioinformatics integrated Weighted Gene Co-expression Network Analysis (WGCNA) to identify co-expressed gene modules and Independent Component Analysis (ICA) for latent factors. Gaussian Process Regression (GPR) models, interpreted via SHAP values, predicted Psoriasis Area and Severity Index (PASI) scores, revealing key drivers of severity.

• Patient cohorts: Discovery (n=89) and replication (n=57).
• Genotyping: HLA imputation using SNP2HLA on Illumina arrays.
• Data accessibility: ArrayExpress E-MTAB-14509 and interactive R Shiny portal.

This rigorous, multi-omics approach bridges genetics, environment, and clinical phenotypes, setting a standard for UK university-led dermatology research. Aspiring researchers can explore similar methodologies in research jobs across UK institutions.

The Nine-Gene Biomarker: A Predictor of Disease Severity

At the core of the findings is a nine-gene signature in lesional skin strongly predictive of psoriasis severity. Derived from turquoise (pro-inflammatory: CARHSP1, KLK13, CRABP2, GJB2) and blue (regulatory: THRA, ZNF34, RORC, CRY2, CACNA2D2) modules, this biomarker captures opposing forces—inflammatory cytokine signalling versus WNT pathway and extracellular matrix regulation.

Positive associations amplify innate and adaptive immunity, while negative ones suggest protective mechanisms. Validated across cohorts, it offers a tool for stratifying patients before treatment, potentially optimising biologic allocation.

HLA Genetic Variants and Their Role in Severity

Integrating genotypes revealed HLA-DQA1*01 and HLA-DRB1*15 alleles positively linked to baseline PASI scores. Factor S18 clustered patients by these variants, with elevated expression correlating to worse disease. Notably, HLA-C*06:02—the strongest psoriasis risk allele—influenced blood factors independently of severity, emphasising susceptibility versus progression distinctions.

These insights illuminate gene-environment interactions, where human leukocyte antigen (HLA) genes, part of the major histocompatibility complex (MHC), present antigens to T-cells, perpetuating inflammation. For UK clinicians, genotyping could soon inform risk stratification.

Explore genetics-focused roles via research assistant jobs in biomedical sciences.

Psoriasis Endotypes: Revealing Molecular Subtypes

The research delineates distinct psoriasis endotypes—stable molecular subtypes underlying clinical variability. Skin endotypes tie to body mass index (BMI), with a 14-gene signature (e.g., SCGB1D2, MMP7, DNER, PDE9A) inversely associated in non-lesional skin, linking metabolic factors to severity. Blood endotypes show adalimumab-specific neutrophil degranulation, absent in ustekinumab, explaining differential side effects.

• Turquoise module/factor S1: Cytokine-driven inflammation (positive severity).
• Blue module/factor S9: WNT/ECM regulation (negative severity).
• BMI endotype: Lightyellow module in skin.

Such subtyping paves the way for endotype-specific therapies, mirroring advances in asthma and cancer.

From Bench to Bedside: Implications for Personalised Treatments

This Newcastle study propels psoriasis towards precision medicine, where biomarkers guide therapy. Currently, UK patients cycle through biologics like secukinumab (IL-17), guselkumab (IL-23), or etanercept (TNF), with 20-40% non-response rates. The signatures could predict responders, minimising exposure to ineffective drugs and side effects.

Nick Reynolds, Professor at Newcastle, noted: "These insights bring us closer to personalised approaches to care." A web portal democratises data exploration, fostering global collaborations.

Read the full study publication or PubMed abstract for technical details.

Current Psoriasis Therapies and the Need for Precision

In the UK, NHS guidelines prioritise topical steroids, vitamin D analogues, then phototherapy (narrowband UVB), and biologics for severe cases. Biologics achieve PASI75 (75% improvement) in 70-90%, but variability persists due to endotypes. Ustekinumab suits IL-23-driven cases; adalimumab targets broader inflammation.

Personalisation via pharmacogenomics, as pioneered here, could enhance efficacy, cut costs (£10,000-20,000/year per patient), and address inequities in access. Newcastle's NIHR Biomedical Research Centre exemplifies translational impact.

Academic professionals advancing therapies may find opportunities in clinical research jobs.

Patient Impacts, Comorbidities, and UK Perspectives

Psoriasis impairs quality of life, with stigma, pain, and depression common. Comorbidities amplify burden: 50% higher cardiovascular risk, psoriatic arthritis in 30%. The study's BMI-severity link stresses holistic management, including lifestyle interventions.

Melinda Spencer of the Psoriasis Association hailed it as "real hope for meaningful difference." In the UK, where prevalence holds at 2%, equitable personalised care could transform lives.

Learn more via Psoriasis Association.

Future Outlook: Trials, AI, and Research Frontiers

Prospective validation of biomarkers in trials, AI-optimised dosing, and single-cell integration loom large. Newcastle's ongoing work, including AI for treatment prediction, signals momentum. Multi-ancestry studies will refine applicability.

Higher education drives this: from PhDs to postdocs. Visit postdoc positions or academic CV advice at AcademicJobs.com.

Career Opportunities in Dermatology and Genomics Research

This study spotlights demand for bioinformaticians, dermatologists, and geneticists in UK universities. Newcastle and collaborators seek talent for precision medicine initiatives. Platforms like university jobs and UK academic roles list openings in lecturer and research posts.

Engage with professors via Rate My Professor; advance your career with higher ed career advice.